Drugs that target NF-κB in vivo are still under research, however mouse ALS model expressing human TDP-43 mutation showed that the extract of herbal medicine Withania somnifera (Ashwagandha) with anti-inflammatory properties reduced NF-κB activity, neuroinflammation, TDP-43 aggregation, and improved neuromuscular innervation (86). This evidence concerns the gene TARDBP and amyotrophic lateral sclerosis.